DLX 105

Drug Profile

DLX 105

Alternative Names: DLX-105; ESBA-105; Humanised single-chain (scFv) antibody directed against human TNF-alpha

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ESBATech
  • Developer Cell Medica; Delenex Therapeutics; ESBATech
  • Class Immunoglobulin fragments
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I/II Behcet's syndrome
  • Preclinical Hidradenitis suppurativa
  • Discontinued Age-related macular degeneration; Crohn's disease; Dry eyes; Ocular inflammation; Osteoarthritis; Uveitis

Most Recent Events

  • 12 Jul 2016 Delenex Therapeutics has been acquired and merged into Cell Medica
  • 06 Oct 2015 Discontinued - Phase-I for Osteoarthritis in Germany (Intra-articular)
  • 06 Oct 2015 Discontinued - Phase-I for Osteoarthritis in Switzerland (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top